Recent Finacing
Recent Raise
Imcyse develops Imotope™ immunotherapies that induce cytolytic CD4+ T cells to selectively eliminate pathogenic immune cells, with clinical programs in type 1 diabetes and multiple sclerosis.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Imcyse.
